Cultural Differences in Treatment Preferences and Perceptions of Acne


Original post, click here

Verified June 2017 by Roopal Kundu, Northwestern University

Sponsor:

Information provided by (Responsible Party):

Roopal Kundu, Northwestern University

ClinicalTrials.gov Identifier:

NCT03192163

First received: June 15, 2017

Last updated: June 15, 2017

Last verified: June 2017

This study will use a survey to examine relationships between culture, race, and ethnicity with treatment preferences and perceptions for acne vulgaris.

Acne Vulgaris Other: Survey

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Cultural, Racial, and Ethnic Differences in Treatment Preferences and Perceptions of Acne Vulgaris

Primary Outcome Measures:

  • Willingness to Pay [ Time Frame: 15 minutes ]

    percentage of income individual is willing to pay to use a treatment that improves his or her acne

  • Preferred and Least Preferred Treatments [ Time Frame: 15 minutes ]

    ranked list of treatments for acne that individuals prefer and don’t prefer using (ie. masks/facials, isotretinoin, etc) and reasons for why individuals prefer or don’t prefer using that treatment (ie. cost, safety, efficacy, etc.)

Estimated Enrollment: 100
Actual Study Start Date: June 2015
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
ResearchMatch Group Other: Survey

31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.

Northwestern Center for Ethnic Skin Group Other: Survey

31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.

The purpose of this study is to determine how explanatory models, perceptions, and treatment preferences of acne vulgaris vary across different cultures and racial and ethnic backgrounds. This study will also use Willingness to Pay to investigate differences in treatment valuation. Clarifying these differences will better inform patient counseling and treatment adherence by improving the quality of shared decision making.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample

Adults with Acne vulgaris in the US

Inclusion Criteria:

  • Subjects must have acne vulgaris, be at least 18 years of age, and must be able to complete a survey published in English.

Exclusion Criteria:

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03192163

Northwestern University Feinberg School of Medicine Department of Dermatology
Chicago, Illinois, United States, 60611
Contact: Roopal V Kundu, MD    312-695-8106    roopal.kundu@nm.org   
Principal Investigator: Roopal V Kundu, MD         

Northwestern University

Study Data/Documents: Survey  This link exits the ClinicalTrials.gov site

This is the RedCap survey that subjects will take.

Responsible Party: Roopal Kundu, Principal Investigator, Northwestern University
ClinicalTrials.gov Identifier: NCT03192163     History of Changes
Other Study ID Numbers: RVK04072017
Study First Received: June 15, 2017
Last Updated: June 15, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases

ClinicalTrials.gov processed this record on June 19, 2017